Composition:
Poze G Tab 30mg/ 2mg: Each tablet contains 30mg pioglitazone hydrochloride with 2 mg glimepiride.
Description:
Poze G tablets contain two oral antihyperglycemic agents used in the management of type 2 diabetes: pioglitazone hydrochloride and glimepiride. Pioglitazone hydrochloride acts primarily by decreasing insulin resistance. It improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. It reduces circulating insulin levels and improves glycemic control. Glimepiride is an oral glucose-lowering drug of the sulphonylurea class, which acts by increasing the release of insulin from the pancreatic beta cells.
Indications:
Poze G is indicated as an adjunct to diet and exercise as a once-daily combination therapy to improve glycemic control in patients with type 2 diabetes who are already treated with a combination of pioglitazone and a sulfonylurea or whose diabetes is not adequately controlled with a sulfonylurea alone, or for those patients who have initially responded to pioglitazone alone and require additional glycemic control.
Dosage:
Poze G tablets are available as a 30mg pioglitazone plus 2mg glimepiride formulation for oral administration. The maximum recommended daily dose for pioglitazone is 45mg and the maximum recommended daily dose for glimepiride is 8mg. Poze G should therefore not be given more than once daily at any of the tablet strengths.
General:
The use of antihyperglycemic therapy in the management of type 2 diabetes should be individualized on the basis of effectiveness and tolerability.
Dosage Recommendations:
Selecting the starting dose of Poze G should be based on the patient’s current regimen of pioglitazone and/or sulfonylurea. It is recommended that a single dose of Poze G be administered once daily with the first main meal.
Starting dose for patients currently on glimepiride monotherapy:
Based on the usual starting dose of pioglitazone (15mg or 30mg daily), Poze G may be initiated at 30mg/2mg tablet strengths once daily, and adjusted after assessing adequacy of therapeutic response.
Starting dose for patients currently on pioglitazone monotherapy:
Based on the usual starting doses of glimepiride (1mg or 2mg once daily), and pioglitazone 15mg or 30mg, Poze G may be initiated at 30mg/2mg once daily, and adjusted after assessing adequacy of therapeutic response.
Starting dose for patients switching from combination therapy of pioglitazone plus glimepiride as separate tablets:
Poze G may be initiated with 30mg/2mg tablet strengths based on the dose of pioglitazone and glimepiride already being taken. Patients who are not controlled with 15 mg of pioglitazone in combination with glimepiride should be carefully monitored when switched to Poze G.
Maximum Recommended Dose:
Poze G tablets are available as a 30mg pioglitazone plus 2mg glimepiride formulation for oral administration. The maximum recommended daily dose for pioglitazone is 45mg and the maximum recommended daily dose for glimepiride is 8mg. Poze G should therefore not be given more than once daily at any of the tablet strengths.